Published in Postgrad Med J on October 01, 2007
Pure seminoma: a review and update. Radiat Oncol (2011) 1.06
Percutaneous testicular biopsy for indeterminate testicular lesions. Br J Radiol (2012) 0.82
Unusually Located Stroke After Chemotherapy in Testicular Germ Cell Tumors. J Investig Med High Impact Case Rep (2015) 0.75
International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol (1997) 8.41
Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet (2005) 3.75
A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol (2005) 3.53
Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med (1987) 3.52
Testicular germ-cell cancer. N Engl J Med (1997) 3.31
Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol (2003) 3.10
Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol (2002) 2.88
Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst (1997) 2.83
Increasing incidence of testicular cancer worldwide: a review. J Urol (2003) 2.76
Mortality after cure of testicular seminoma. J Clin Oncol (2004) 2.53
Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol (1997) 2.29
Localization to Xq27 of a susceptibility gene for testicular germ-cell tumours. Nat Genet (2000) 2.26
Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. J Clin Oncol (1999) 2.25
Epidemiology of testicular cancer: an overview. Int J Cancer (2005) 1.80
Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol (1998) 1.72
2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol (2004) 1.69
Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: a Spanish Germ Cell Cancer Group Study. J Clin Oncol (2008) 1.62
Fertility in Norwegian testicular cancer patients. Br J Cancer (2000) 1.59
Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. J Clin Oncol (2003) 1.44
Genetic predisposition to testicular germ-cell tumours. Lancet Oncol (2004) 1.28
The role of maintenance therapy in disseminated testicular cancer. N Engl J Med (1981) 1.22
Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol (2000) 1.21
Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol (1995) 1.16
Fertility, gonadal and sexual function in survivors of testicular cancer. Br J Cancer (2005) 1.15
Carcinoma in situ testis, the progenitor of testicular germ cell tumours: a clinical review. Ann Oncol (2005) 1.11
Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors. J Clin Oncol (2003) 1.09
Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol (2003) 1.08
Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis. Cancer (1998) 1.07
A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial. Br J Cancer (2005) 1.06
Long-term follow-up of Anglian Germ Cell Cancer Group surveillance versus patients with Stage 1 nonseminoma treated with adjuvant chemotherapy. Urology (2004) 1.05
The role of retroperitoneal lymph node dissection in the management of testicular cancer. Urol Oncol (2004) 1.03
High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. J Clin Oncol (2000) 1.02
Testicular-sparing surgery: a reasonable option in selected patients with testicular lesions. BJU Int (2003) 1.02
Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indian University experience. J Clin Oncol (1998) 1.01
Clinical relevance of the i(12p) marker chromosome in germ cell tumors. J Natl Cancer Inst (1994) 0.98
Interdisciplinary consensus on diagnosis and treatment of testicular germ cell tumors: result of an update conference on evidence-based medicine (EBM). Eur Urol (2001) 0.92
Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study. Ann Oncol (2004) 0.88
Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol (2004) 0.88
Fertility after testicular cancer treatments: results of a large multicenter study. Cancer (2004) 0.88
Management of post-chemotherapy residual masses in advanced seminoma. J Urol (2002) 0.88
A molecular model for the development of germ cell cancer. Int J Cancer (1999) 0.86
Radiotherapy for stages I and IIA/B testicular seminoma. Int J Cancer (1999) 0.83
Oxaliplatin and irinotecan plus granulocyte-colony stimulating factor as third-line treatment in relapsed or cisplatin-refractory germ-cell tumor patients: a phase II study. Eur Urol (2004) 0.81
Prediction of relapse after lymph node dissection for germ cell tumours: can salvage chemotherapy be avoided? Br J Cancer (2001) 0.78
The role of ultrasound in diagnosis and staging of testicular cancer. Semin Urol (1988) 0.77
Retroperitoneal lymph node dissection for the management of clinical stage I nonseminoma. J Urol (2000) 0.77
Residual mass following chemotherapy of seminoma. Ann Oncol (1997) 0.77
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med (2015) 5.39
Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. Lancet Oncol (2012) 2.06
An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer. Eur J Cancer (2012) 1.97
REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. Clin Cancer Res (2010) 1.53
Extracorporeal high intensity focused ultrasound for renal tumours: a 3-year follow-up. BJU Int (2010) 1.05
Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study. Eur J Cancer (2012) 1.04
Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia. Arthritis Res Ther (2004) 1.04
The type 1 insulin-like growth factor receptor is over-expressed in bladder cancer. BJU Int (2007) 0.98
Active surveillance of small renal masses offers short-term oncological efficacy equivalent to radical and partial nephrectomy. BJU Int (2012) 0.94
Recent advances in urinary bladder cancer detection. Expert Rev Anticancer Ther (2012) 0.92
Cisplatin-associated thrombosis. Anticancer Drugs (2008) 0.87
Acute necrotizing sinusitis caused by Staphylococcus lugdunensis. J Clin Microbiol (2011) 0.85
A first-in-man phase i and pharmacokinetic study on CHR-2797 (Tosedostat), an inhibitor of M1 aminopeptidases, in patients with advanced solid tumors. Clin Cancer Res (2009) 0.82
An adult Xp11.2 translocation renal carcinoma showing response to treatment with sunitinib. Urol Oncol (2009) 0.80
Automated uro-oncology data collection: the Cancer Research Uro-Oncology Database. BJU Int (2009) 0.76
The hazards of cross comparing the drug toxicity results from different trials in metastatic renal cancer: in response to a letter from Dr. Catalá-López. Eur J Cancer (2012) 0.75
Blastic plasmacytoid dendritic cell neoplasm presenting as a renal mass. Histopathology (2011) 0.75